JNJ
Johnson JohnsonCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bullish case is that JNJ has already shown enough Q1 evidence of portfolio breadth to defend earnings quality: raised 2026 guidance, strong oncology and cardiovascular/MedTech trends, and several recent approvals and launches create a credible path to steadier acceleration into year-end.
Posture
Mixed
Lead driver
Value
What changed
6 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Commercial uptake for newer launches may not scale fast enough to offset mature-brand erosion.
Momentum
41
Value
62
Sentiment
57
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $242.00 · Bull $258.00 · Bear $218.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $240.57
Why
Momentum41 · Δ7d -2.5
Value62 · Δ7d +0.5
Sentiment57 · Δ7d +8.0
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
41
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.5
Δ21d
+16.6
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+0.6
Sentiment
57
33% active weight
Current posture
7d trendImproving
Δ7d
+8.0
Δ21d
+7.2
Why this grade
Composite grade C. Momentum 41.5 / Value 61.8 / Sentiment 56.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$538.04B
Beta
0.34
Shares Out
2.41B
P/E (TTM)
19.7
P/S (TTM)
5.34
P/FCF (TTM)
66.85
Rev YoY
+6.8%
EPS YoY
+91.2%
Gross Margin
+68.1%
Op Margin
+34.2%
Net Debt
$12.11B
Current Ratio
1.07
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology